Table 4 Characteristics of studies comparing outcome for continuous versus intermittent administration of carbapenems
Study | Drug | Patient population | Dosage | Study type | Outcome measure | Outcome | Remarks |
|---|---|---|---|---|---|---|---|
*Lorente 2006 [53] | Meropenem | VAP with gram negative bacilli | 4 g/d CI (n = 42) vs. 4 x 1 g/d (n = 47) | Retrospective cohort study | Clinical cure | CI > II(p  < 0.001) |  |
*Sakka 2007 [44] | Imipenem-cilastatin | Nosocomial pneumonia | 2 g/d CI (n = 10) vs. 3 x 1 g/d (n = 10) | RCT | Clinical cure | NS | Lower antimicrobial dose in CI groupT > MIC = 100 % in both II and CI group |